Current perspectives on British use of adjunctive therapies during coronary interventions

International Journal of Cardiology

Volumn 79, Issue 2-3, 2001, Pages 119-125

  Swanson, Neil ^a   Hogrefe, Kai ^a   Stephens Lloyd, Amanda ^a   Gershlick, Anthony ^a  

^a GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Abciximab; Angioplasty; Clopidogrel; Heparin

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN; TICLOPIDINE;

ARTICLE; CARDIOLOGY; CORONARY ARTERY DILATATION; CORONARY STENT; DRUG USE; HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED KINGDOM;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; COMBINED MODALITY THERAPY; CORONARY DISEASE; GREAT BRITAIN; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TICLOPIDINE;

EID: 0034926858     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(01)00446-6     Document Type: Article

References (19)

1. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
4. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of platelet IIb/IIIa inhibitor for stenting
6. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
7. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: Analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial
8. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting
9. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: The multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS)
10. Low-dose heparin for routine coronary angioplasty and stenting
11. Two hour ambulation after coronary angioplasty and stenting with 6 F guiding catheters and low dose heparin
12. Clopidogrel for the prevention of stent thrombosis
13. Minimal myocardial damage during coronary intervention is associated with impaired outcome
14. Efficacy of abciximab readministration in coronary intervention
15. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
16. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
17. Is clopidogrel a safe and effective adjunctive anti-platelet therapy for coronary artery stenting?
18. An informational versus monetary incentive in increasing physicians' response rates